Skip to main content
. Author manuscript; available in PMC: 2009 Oct 27.
Published in final edited form as: Cancer Prev Res (Phila). 2008 Oct;1(5):316–328. doi: 10.1158/1940-6207.CAPR-07-0002

Figure 3. IL-1β significantly augments the angiogenic activity of NSCLC by inducing the expression of angiogenic CXC chemokine genes.

Figure 3

A, CM was collected from A549 cells treated with either control medium (a) or medium containing 2.5 ng/ml of IL-1β (b) for 24 h and CM from IL-1β-treated A549 cells was preincubated with 10 µg/mL of non-immune IgG (c) or an anti-CXCL5 monoclonal antibody (d) or an anti-CXCL8 monoclonal antibody (e) or an anti-CXCR2 monoclonal antibody (f) or an anti-VEGF monoclonal antibody (g) at 37°C for 1 h. A migration assay was performed by stimulating HUVECs with the indicated CM as described in Materials and Methods. Migrated dells were photographed after 16 h of incubation at 37°C. B, Image analysis of HUVECs migration was quantified using the ImageJ software program. Data were expressed as the mean ± SE. *, p<0.05.